KOSDAQBiotech & Pharma243070

Huons

₩15,180▲ 0.86%2026-11-18 close
Market Cap
₩181.9B
Turnover
₩500M
Volume
30K
Shares out.
12M
PER
6.5×
PBR
0.5×
EPS
₩2,324
Dividend Yield
6.13%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩920 per share · Prices as of the 2026-11-18 close

01

Report overview

Back in the Red as Vaccine and Toxin Lines Test the Recovery

Huons swung to an operating loss in the third quarter of 2026 and cut its full-year revenue outlook, so vaccine distribution and margin recovery are the next points to verify.

  1. 1

    Third-quarter 2026 revenue was KRW 144 billion, down 6.3% year on year, and the company swung to an operating loss of KRW 4.47 billion.

  2. 2

    The full-year revenue outlook was cut from KRW 646.2 billion to KRW 584.6 billion, about 9.5% below the earlier forecast.

  3. 3

    Revenue in 2025 was KRW 620.8 billion, rising for three consecutive years, while operating profit was KRW 45.6 billion, up 14.9%, and the operating margin was 7.3%.

  4. 4

    Third-quarter 2026 net income attributable to controlling shareholders was KRW 16.1 billion, moving opposite to the operating loss, and how much non-operating items contributed will be checked in the annual report.

  5. 5

    The debt ratio fell to 64.0% at the end of 2025 from 72.9% in 2024.

02

Business structure

Huons is a pharmaceutical company built around prescription drugs, beauty and wellbeing products, and contract manufacturing (CMO). In the third quarter of 2025, prescription drug revenue was KRW 70 billion, up 5.1% year on year, and revenue from its flagship anesthetic rose 44% year on year.

CMO revenue reached KRW 19.9 billion, up 28.0%, supported by higher utilization of the eye drop line at Plant 2. Beauty and wellbeing revenue fell 27.6% to KRW 35.3 billion because the health functional food unit was transferred to subsidiary Huons N.

Excluding the transferred business, revenue was KRW 34.7 billion, up 0.1%. Subsidiary Huons N posted third-quarter 2026 revenue of KRW 21.8 billion, up 12.5% year on year.

Botulinum toxin is handled by subsidiary Huons BioPharma, whose third-quarter 2026 revenue rose 32.8% from the prior quarter to KRW 10.4 billion on higher Chinese toxin exports. The company began its vaccine distribution business in April 2026, and its continuous glucose monitor business ended.

In an August 2024 report, prescription drugs accounted for 44% of first-half sales and beauty and wellbeing products for 33%. Competitors in botulinum toxin include Hugel and PharmaResearch.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩153.7B₩9.9B6.4%
2025Q4₩165.2B₩9.8B5.9%
2026Q1₩141.9B-₩600M−0.5%
2026Q2₩147B₩2.9B2.0%
2026Q3₩144B-₩4.5B−3.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩492.4B₩40.9B₩22.4B8.3%7.9%64.4%
2023₩552B₩56B₩50.5B10.1%15.5%62.6%
2024₩590.2B₩39.7B₩29.5B6.7%8.5%72.9%
2025₩620.8B₩45.6B₩42.7B7.3%11.4%64.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Huons' reported results peaked in 2023, dipped, and recovered in 2025. Revenue rose from KRW 492.4 billion in 2022 to KRW 552 billion in 2023, up 12.1%, then to KRW 590.2 billion in 2024, up 6.9%, and to KRW 620.8 billion in 2025, up 5.2%, marking three consecutive years of growth from 2023 through 2025.

Operating profit was KRW 56 billion in 2023, the largest year of 2022 to 2025, and KRW 39.7 billion in 2024, down 29.1%, the smallest year. Operating profit in 2025 was KRW 45.6 billion, up 14.9%, with an operating margin of 7.3%, above 6.7% in 2024 but below 10.1% in 2023.

Net income attributable to controlling shareholders was KRW 50.5 billion in 2023, the largest year, and recovered to KRW 42.7 billion in 2025, up 44.8%. Net income including non-controlling interests was KRW 42.2 billion in 2025 and is a different figure from controlling-shareholder net income.

Operating cash flow was KRW 45 billion in 2025, below KRW 52.6 billion in 2024. Quarterly, the fourth quarter of 2025 posted revenue of KRW 165.2 billion, up 7.5% from the prior quarter, and operating profit of KRW 9.82 billion, before the first quarter of 2026 swung to an operating loss of KRW 649 million.

The second quarter returned to operating profit of KRW 2.93 billion, but the third quarter posted revenue of KRW 144 billion, down 6.3% year on year, and an operating loss of KRW 4.47 billion.

The company attributed the sales decline to the end of its continuous glucose monitor business and the absence of US exports, and the profit squeeze to higher cost of sales, R&D spending, and added recall costs on a US export product.

Third-quarter R&D rose 13.9% year on year and 21% from the prior quarter, and cumulative R&D for the first three quarters of 2026 was KRW 7.9 billion, up 24.8%, about 4.9% of sales.

Third-quarter net income attributable to controlling shareholders was KRW 16.1 billion, up 103.8% year on year, moving in the opposite direction from the operating loss; how non-operating items contributed will be checked in the regular report line items. Over the last four quarters, net income attributable to controlling shareholders totaled KRW 2.71 billion.

05

Industry analysis

Among Korean pharmaceutical companies, Huons combines a prescription drug core with eye drop and injectable contract manufacturing. The recovery in US injectable exports and higher eye drop CMO volumes lifted results in the third quarter of 2025.

In the third quarter of 2026, however, there were no US export sales, which made overseas shipments a source of quarterly swings. Botulinum toxin exports to China have emerged as a new growth lever. In domestic botulinum toxin, the company competes with Hugel and PharmaResearch.

Vaccine and domestic drug sales kept growing in the third quarter of 2026. CMO revenue depends on line utilization, which lifted sales in the third quarter of 2025. Vaccine distribution is a new business started in April 2026 with a distribution model different from its prescription drug business.

Assessing where Huons sits in the industry cycle requires comparing peers such as SK Bioscience and Samsung Biologics on quarterly results and order flow.

06

Outlook

In a corrected filing dated November 12, 2026, the company lowered its full-year revenue outlook from KRW 646.2 billion to KRW 584.6 billion, a cut of about 9.5% from the earlier forecast.

The company plans to expand its vaccine distribution business to restore sales and to focus on margin improvement through cost discipline. In the R&D pipeline, a new drug trial began enrolling its first patient in July 2026.

Raising utilization at the second plant was cited as a medium-term priority in the third quarter of 2025. The company decided a cash dividend for the third quarter of 2026, which it described as a reduced dividend funded by transferring capital reserves to retained earnings.

The record date is December 4 and the scheduled payment date is December 22. The next regular report, the 2026 annual report, will show progress against the revenue outlook and fourth-quarter results.

Because the outlook of KRW 584.6 billion sits below the 2025 reported revenue of KRW 620.8 billion, the guidance implies lower revenue in 2026 than in 2025. The contribution of vaccine distribution and toxin exports to recovering that outlook is the next point to check.

07

Valuation

PER
6.5×
PBR
0.5×
ROE
7.2%
EPS
₩2,324
BPS
₩33,132
Dividend per share
₩920

Valuation should be read together with the share price level, net asset value, and earnings trend. The price-to-book ratio sits below 1x, meaning the market values the company below its controlling-shareholder equity of KRW 373.9 billion. This is a comparison against book value, not a standalone measure of fair value.

On earnings, controlling-shareholder net income recovered from KRW 22.4 billion in 2022 to KRW 42.7 billion in 2025. However, the third-quarter 2026 operating loss puts the question of whether that recovery continues quarter to quarter in focus.

Over the last four quarters, controlling-shareholder net income totaled KRW 2.71 billion, showing how volatile quarterly profit has been. The dividend is a reduced dividend funded by capital reserves, so its sustainability should be assessed separately from the earnings trend. How the share price is read depends mainly on whether operating profit returns consistently.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Annual recovery and balance sheet improvement

Revenue in 2025 was KRW 620.8 billion, rising for three consecutive years, and operating profit was KRW 45.6 billion, up 14.9%. The debt ratio fell to 64.0% from 72.9% in 2024. Net income attributable to controlling shareholders rose 44.8% to KRW 42.7 billion, confirming the direction of recovery in the figures.

New businesses and toxin export growth

The vaccine distribution business started in April 2026 and was presented as a means to restore revenue. Subsidiary Huons BioPharma's botulinum toxin revenue reached KRW 10.4 billion in the third quarter of 2026, up 32.8% from the prior quarter on higher Chinese exports. CMO revenue rose 28.0% in the third quarter of 2025, confirming growth in contract manufacturing.

Quarterly return to profit

Operating profit returned to KRW 2.93 billion in the second quarter of 2026 from an operating loss of KRW 649 million in the first quarter. Net income attributable to controlling shareholders reached KRW 16.1 billion in the third quarter of 2026, up 103.8% year on year. Whether the return to operating profit continues quarter to quarter is the next point to check.

09

Bear factors

Shrinking top line and lowered outlook

Third-quarter 2026 revenue was KRW 144 billion, down 6.3% year on year, and the full-year outlook was lowered by KRW 61.6 billion. The end of the continuous glucose monitor business and the absence of US exports were cited as causes. Vaccine and domestic drug sales grew but did not offset the overall decline.

Third-quarter operating loss and cost pressure

The third-quarter 2026 operating loss was KRW 4.47 billion, a swing into loss. R&D rose 13.9% year on year and 21% from the prior quarter. Higher cost of sales and recall costs on a US export product added to the pressure.

Divergence between operating and net results

Net income attributable to controlling shareholders swung from a KRW 248 million loss in the second quarter of 2026 to KRW 16.1 billion in the third quarter. Because operating and net results moved in opposite directions, the composition of profit should be checked in the annual report's income statement details. Operating profit also fell 29.1% to KRW 39.7 billion in 2024.

10

Risk factors

Quality and regulatory risk

Added recall costs on a US export product weighed on third-quarter 2026 profitability. Whether exports resume and whether quality issues recur will directly affect results. The third quarter showed how quarterly results can swing when they depend on export products.

R&D spending burden

Cumulative R&D for the first three quarters of 2026 was KRW 7.9 billion, up 24.8%. The new drug trial began enrolling its first patient in July 2026, but results and commercialization timing remain uncertain. Expanded R&D is weighing on near-term profit.

Dividend funding structure

This dividend is a reduced dividend funded by transferring capital reserves to retained earnings. If operating losses persist, the sustainability of this funding structure becomes an important consideration. The durability of dividends depends on both earnings recovery and the funding structure.

11

What to watch next

  1. December 4, 2026

    Record date for the third-quarter dividend. The record date is December 4 and payment is scheduled for December 22, a point to check the funding and continuity of shareholder returns.

  2. December 22, 2026

    Scheduled dividend payment date. It is the point to confirm that payment proceeds as planned under the reduced-dividend structure.

  3. January to February 2027 (date TBD)

    Expected timing of the fourth-quarter 2026 preliminary results. It is the point to check whether the KRW 584.6 billion revenue outlook and fourth-quarter operating results line up.

  4. End of March 2027

    Filing timing for the 2026 annual report, the next regular report. It shows progress against the revenue outlook, operating margin, debt ratio, and quarterly income details.

12

Overall view

Huons' reported 2025 results show three consecutive years of revenue growth, operating profit of KRW 45.6 billion, and a debt ratio of 64.0%, pointing to recovery and a stronger balance sheet.

However, the third-quarter 2026 operating loss of KRW 4.47 billion and the lowered revenue outlook from KRW 646.2 billion to KRW 584.6 billion show near-term pressure on profitability and top line. Higher R&D, the absence of US exports, recall costs, and the end of the glucose monitor business acted together.

Strengths include vaccine distribution expansion, toxin exports to China, CMO growth, and the return to operating profit in the second quarter of 2026. Weaknesses include the renewed third-quarter loss, the lowered outlook, the funding structure of the reduced dividend, and uncertainty in the new drug trial.

The next points to check are the fourth-quarter 2026 preliminary results, the margin and outlook progress in the 2026 annual report, vaccine distribution revenue scale, and whether US exports resume. How the share price is read depends on whether profit recovery continues quarter to quarter.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. fintechtimes.co.kr
  2. medipharmhealth.co.kr
  3. news.jkn.co.kr
  4. inthenews.co.kr
  5. news.jkn.co.kr
  6. sentv.co.kr
  7. medicaldaily.co.kr
  8. mydaily.co.kr
  9. todaymild.com
  10. newsthevoice.com
  11. news1.kr
  12. m.jobkorea.co.kr
  13. mimint.co.kr
  14. huonsglobal.com
  15. intn.co.kr
  16. startuptoday.co.kr
  17. hitnews.co.kr
  18. huons.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis